We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vaccine Effectively Protects Mice against RSV Infection

By LabMedica International staff writers
Posted on 26 Dec 2018
Print article
Image: This transmission electron micrograph (TEM) depicts the liberated, chain-like, ribonucleic acid (RNA) genome of the respiratory syncytial virus (RSV) pathogen. RSV is a negative-sense, enveloped RNA virus. The virion is variable in shape and size, with a diameter ranging between 120 and 300 nanometers (Photo courtesy of the CDC).
Image: This transmission electron micrograph (TEM) depicts the liberated, chain-like, ribonucleic acid (RNA) genome of the respiratory syncytial virus (RSV) pathogen. RSV is a negative-sense, enveloped RNA virus. The virion is variable in shape and size, with a diameter ranging between 120 and 300 nanometers (Photo courtesy of the CDC).
The potential of a microneedle skin patch for vaccination against respiratory syncytial virus (RSV) has been demonstrated in a mouse model system.

RSV is a common respiratory disease, but it can be serious for young children, patients with compromised immune systems, and the elderly. Intramuscular (IM) vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) failed in clinical trials to protect against infection due to vaccine-enhanced respiratory disease.

In the current study, investigators at Georgia State University (Atlanta, USA) tested the efficacy of skin vaccination against RSV. They analyzed the immunogenicity, efficacy, and inflammatory disease after microneedle (MN) patch delivery of FI-RSV vaccine (FI-RSV MN) to the mouse skin with or without an adjuvant of monophosphoryl lipid A (MPL).

The investigators reported in the October 26, 2018, online edition of the journal PLOS ONE that compared to IM vaccination, MN patch delivery of FI-RSV was more effective in clearing lung viral loads and preventing weight loss, and in diminishing inflammation, infiltrating immune cells, and T-helper type 2 (Th2) CD4 T cell responses after RSV challenge. With MPL adjuvant, MN patch delivery of FI-RSV significantly increased the immunogenicity and efficacy as well as preventing RSV disease as evidenced by lung viral clearance and avoiding pulmonary histopathology.

The investigators suggested that delivery of RSV vaccines to the skin via a MN patch would be highly attractive for children who have needle-phobia of intramuscular (IM) needle injection. Also, MN patch vaccination would induce a different profile of immune responses that could be more effective in preventing RSV vaccine-enhanced disease due to targeted skin dendritic cells.

"Skin delivery of RSV vaccines with an appropriate adjuvant can be translational to the clinic," said senior author Dr. Sang-Moo Kang, professor of biomedical sciences at Georgia State University.

Related Links:
Georgia State University

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.